Clinical trial
Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast
NCT00165256 · Dana-Farber Cancer Institute, Other · Active, not recruiting
Key facts
| NCT number | NCT00165256 |
|---|---|
| Title | Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast |
| Official title | Wide Excision Alone for DCIS-Grades 1 and 2 |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ductal Carcinoma in Situ of the Breast |
| Intervention type | Other |
| Interventions | Observation |
| Enrollment | 158 |
| Start date | May 1, 1995 |
| Primary completion | Jul 1, 2002 |
| Completion | Dec 1, 2027 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 29, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: